Ocugen Shares Spike Higher As Traders Circulate Earlier Tweet (From ~50 Mins Ago) From Economic Times ‘Scientific conjecture says [Ocugen partner, Bharat’s] Covaxin more effective against Omicron’
https://twitter.com/EconomicTimes/status/1466056967877652484?s=20
20 Stocks Moving in Monday’s Pre-Market Session
Gainers
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results were down year over year.
Ocugen-Partnered Bharat Biotech’s COVID-19 Shot Shows 50% Effectiveness In Small Study In India
Bharat Biotech's vaccine was found to be 50% effective at preventing symptomatic COVID-19 in a high-risk population during the second wave of infections in India this year, data gleaned from hospital workers showed. Bharat Biotech's U.S.
Watching Shares Of Ocugen; Traders Circulate The Lancet Report Titled ‘Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study’
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00674-5/fulltext
Ocugen Issues Statement Regarding Publication Of COVAXIN (BBV152) Phase 3 Study Results In The Lancet
https://ocugen.gcs-web.com/news-releases/news-release-details/ocugen-statement-regarding-publication-covaxintm-bbv152-phase-3
Ocugen Shares Quiet Following Headline Gates Ventures, Coalition for Epidemic Preparedness Innovations Will Fund Indian Vaccine Makers; BZ NOTE: Ocugen Is COVID-19 Vaccine Partner For India’s Bharat Biotech
https://www.livemint.com/companies/news/gatesventures-cepi-plan-to-fund-indian-vaccine-makers-11636482311164.html
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Ocugen Q3 EPS $(0.05) Misses $(0.04) Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 150 percent decrease over losses of $(0.02) per share from the same